Emerging therapeutic targets in allergy: IL-4Rα and Stat6

Expert Opinion on Therapeutic Targets

Volumn 3, Issue 3, 1999, Pages 381-389

  Izuhara, Kenji ^a   Shirakawa, Taro ^b   Adra, Chaker N ^c   Hamasaki, Naotaka ^a   Hopkin, Julian M ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

allergy; anti interleukin 4 receptor chain antibody; IgE; interkeukin 4 mutein; interleukin 13; interleukin 4; interleukin 4 receptor chain; interleukin 4 2; protein inhibitor of activated Stat; soluble interleukin 4 receptor chain; Stat6; suppressor of cytokine signalling

Indexed keywords

EID: 0042077866     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.3.3.381     Document Type: Review

References (73)

1. IZUHARA K, SHIRAKAWA T: Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int. J. Mol. Med. (1999) 3:3-10.
2. COHN L, TEPPER JS, BOTTOMLY K: IL-4-independent induction of airway hyper-responsiveness by Th2, but not Th1, cells. J. Immunol. (1998) 161:3813-3816. (Pubitemid 28468952)
3. ROMAGNANI S: Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy Immunol. (1992) 98:279-285.
4. RICCI M, MATUCCI A, ROSSI O: IL-4 as a key factor influencing the development of allergen-specific Th2-like cells in atopic individuals. J. Investig. Allergol. Clin. Immunol. (1997) 7:144-150. (Pubitemid 27344626)
5. WILLS-KARP M, LUYIMBAZI J, XU X et al.: Interleukin-13: central mediator of allergic asthma. Science (1998) 282:2258-2261. (Pubitemid 29004074)
6. GRåNIG G, WARNOCK M, WAKIL AE et al.: Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 282:2261-2263. (Pubitemid 29004075)
7. MITSUYASU H, IZUHARA K, MAO X-Q et al.: Ile50Val variant of IL4Ra upregulates IgE synthesis and associates with atopic asthma. Nature Genet. (1998) 19:119-120.
8. MITSUYASU H, YANAGIHARA Y, MAO X-Q et al.: Dominant effect of Ile50Val variant of the human interleukin-4 receptor a chain in IgE synthesis. J. Immunol. (1999) 162:1227-1231. (Pubitemid 29306989)
9. KISHIMOTO T, TAGA T, AKIRA S: Cytokine signal transduction. Cell (1994) 76:253-262. (Pubitemid 24046688)
10. LEONARD WJ, SHORES EW, LOVE PE: Role of the common cytokine receptor g chain in cytokine signaling and lymphoid development. Immunol. Rev. (1995) 148:97-114. (Pubitemid 26010544)
11. AMAN MJ, TAYEBI N, OBIRI NI et al.: cDNA cloning and characterization of the human interleukin 13 receptor a chain. J. Biol. Chem. (1996) 271:29265-29270. (Pubitemid 26382639)
12. MURATA T, TAGUCHI J, PURI RK: Interleukin-13 receptor a but not a chain: a functional component of interleukin-4 receptors. Blood (1998) 91:3884-3891. (Pubitemid 28225757)
13. CAPUT D, LAURENT P, KAGHAD M et al.: Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor a chain. J. Biol. Chem. (1996) 271:16921-16926. (Pubitemid 26239062)
14. DONALDSON DD, WHITTERS MJ, FITZ LJ et al.: The murine IL-13 receptor a2: molecular cloning, characterization, and comparison with murine IL-13 receptor a1. J. Immunol. (1998) 161:2317-2324. (Pubitemid 28397044)
15. URBAN JFJ, NOBEN-TRAUTH N, DONALDSON DD et al.: IL-13, IL-4Ra, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity (1998) 8:255-264. (Pubitemid 28123752)
16. SCHINDLER C, DARNELL, JR., JE: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann. Rev. Biochem. (1995) 64:621-651.
17. IHLE JN: Cytokine receptor signaling. Nature (1995) 377:591-594.
18. LIN J-X, MIGONE T-S, TSANG M et al.: The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity (1995) 2:331-339.
19. WELHAM MJ, LEARMONTH L, BONE H et al.: Interleukin-13 signal transduction in lymphohemopoietic cells: similarities and differences in signal transduction with interleukin-4 and insulin. J. Biol. Chem. (1995) 270:12286-12296.
20. ORCHANSKY PL, AYRES SD, HILTON DJ et al.: An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits response to IL-4. J. Biol. Chem. (1997) 272:22940-22947. (Pubitemid 27386118)
21. TAKEDA K, TANAKA T, SHI W et al.: Essential role of Stat6 in IL-4 signaling. Nature (1996) 380:627-630. (Pubitemid 26119015)
22. SHIMODA K, VAN DEURSEN J, SANGSTER MY et al.: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 380:630-633. (Pubitemid 26119016)
23. KAPLAN MH, SCHINDLER U, SMILEY ST et al.: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity (1996) 4:313-319. (Pubitemid 26132509)
24. DELPHIN S, STAVNEZER J: Characterization of an interleukin 4 (IL-4) responsive region in the immunoglobulin heavy chain germline e promoter: regulation by NF-IL-4, a C/EBP family member and NF-kB/p50. J. Exp. Med. (1995) 181:181-192.
25. MIKITA T, CAMPBELL D, WU P et al.: Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol. Cell. Biol. (1996) 16:5811-5820. (Pubitemid 26315102)
26. TAKEDA K, KAMANAKA M, TANAKA T et al.: Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J. Immunol. (1996) 157:3220-3222. (Pubitemid 126449129)
27. MOSLEY B, BECKMANN P, MARCH CJ et al.: The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell (1989) 59:335-348. (Pubitemid 19264378)
28. WRIGHTON N, CAMPBELL L, HARADA N et al.: The murine interleukin-4 receptor gene: genomic structure, expression and potential for alternative splicing. Growth Factors (1992) 6:103-118.
29. BLUM H, WOLF M, ENSSLE K et al.: Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J. Immunol. (1996) 157:1846-1853. (Pubitemid 126449655)
30. FANSLOW WC, CLIFFORD K, VANDENBOS T et al.: A soluble form of the interleukin 4 receptor in biological fluids. Cytokine (1990) 2:398-401.
31. FERNANDEZ-BOTRAN R, VITETTA ES: A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA (1990) 87:4202-4206.
32. MALISZEWSKI CR, SATO TA, BOS TV et al.: Cytokine receptors and B-cell functions. J. Immunol. (1990) 144:3028-3033.
33. FANSLOW WC, CLIFFORD KN, PARK LS et al.: Regulation of alloreactivity in vivo by IL-4 and soluble IL-4 receptor. J. Immunol. (1991) 147:535-540.
34. GESSNER A, SCHRàPPEL K, WILL A et al.: Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis. Infect. Immun. (1994) 62:4112-4117. (Pubitemid 24301931)
35. PUCCETTI P, MENCACCI A, CENCI E et al.: Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Infect. Dis. (1994) 169:1325-1331. (Pubitemid 24164598)
36. SATO TA, WIDMER MB, FINKELMAN FD et al.: Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J. Immunol. (1993) 150:2717-2723. (Pubitemid 23127521)
37. RENZ H, BRADLEY K, ENSSLE K et al.: Prevention of the development of immediate hypersensitivity and airway hyper-responsiveness following in vivo treatment with soluble IL-4 receptor. Int. Arch. Allergy Immunol. (1996) 109:167-176. (Pubitemid 26029384)
38. SCHAUER U, SCHMITT M, MåLLER S et al.: Soluble interleukin-4 receptor in atopic children. Int. Arch. Allergy Immunol. (1995) 108:175-182.
39. SANG DK, OUMA JH, JOHN CC et al.: Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J. Infect. Dis. (1999) 179:743-746. (Pubitemid 30016168)
40. GARRONE P, DJOSSOU O, GALIZZI J-P et al.: A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes. Eur. J. Immunol. (1991) 21:1365-1369.
41. BORISH L, NELSON H, NATHAN B et al.: Phase I nebulization study of recombinant human IL-4 receptor (rhuIL-4R) in adult patients with mild atopic asthma. J. Allergy Clin. Immunol. (1998) 99:S413.
42. POWERS R, GARRETT DS, MARCH CJ et al.: Threedimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science (1992) 256:1673-1677.
43. WALTER MR, COOK WJ, ZHAO BGet al.: Crystal structure of recombinant human interleukin-4. J. Biol. Chem. (1992) 267:20371-20376.
44. WLODAVER A, PAVLOVSKY A, GUSTCHINA A: Crystal structure of human recombinant interleukin-4 at 2.25A resolution. FEBS Lett. (1992) 309:59-64.
45. KRUSE N, SHEN B-J, ARNOLD S et al.: Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. EMBO J. (1993) 12:5121-5129. (Pubitemid 23358502)
46. KRUSE N, LEHRNBECHER T, SEBALD W: Site-directed mutagenesis reveals the importance of disulfide bridges and aromatic residues for structure and proliferative activity of human interleukin-4. FEBS Lett. (1991) 286:58-60.
47. KRUSE N, TONY H-P, SEBALD W: Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J. (1992) 11:3237-3244.
48. AVERSA G, PUNNONEN J, COCKS BG et al.: An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J. Exp. Med. (1993) 178:2213-2218. (Pubitemid 23344880)
49. CARBALLIDO JM, SCHOLS D, NAMIKAWA R et al.: IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist. J. Immunol. (1995) 155:4162-4170.
50. SORNASSE T, LARENAS PV, DAVIS KA et al.: Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level. J. Exp. Med. (1996) 184:473-483. (Pubitemid 26324101)
51. ZURAWSKI SM, VEGA F, JR., HUYGHE B et al.: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. (1993) 12:2663-2670. (Pubitemid 23218315)
52. FENG N, LUGLI SM, SCHNYDER B et al.: The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the non-signaling interleukin-13 receptor a2. Lab. Invest. (1998) 78:591-602. (Pubitemid 28246983)
53. SHANAFELT AB, FORTE CP, KASPER JJ et al.: An immune cell-selective interleukin 4 agonist. Proc. Natl. Acad. Sci. USA (1998) 95:9454-9458. (Pubitemid 28506252)
54. TONY HP, SHEN BJ, REUSCH P et al.: Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur. J. Immunol. (1994) 225:659-665. (Pubitemid 24325584)
55. ARAI N, ARAI K: IL-4 Gene: regulation of expression. In: IL-4: Structure and Function. Spits H (Ed), CRC Press, Boca Raton (1992):3-13.
56. SORG RV, ENCZMANN J, SORG UR et al.: Identification of an alternatively spliced transcript of human interleukin-4 lacking the sequence encoded by exon 2. Exp. Hematol. (1993) 21:560-563. (Pubitemid 24212351)
57. ALMS WJ, ATAMAS SP, YUROVSKY VY et al.: Generation of a variant of human interleukin-4 by alternative splicing. Mol. Immunol. (1996) 33:361-370. (Pubitemid 26191480)
58. ATAMAS SP, CHOI J, YUROVSKY VV et al.: An alternative splice variant of human IL-4, IL-4d2, inhibits IL-4-stimulated T cell proliferation. J. Immunol. (1996) 156:435-442.
59. ARINOBU Y, ATAMAS SP, OTSUKA T et al.: Antagonistic effects of an alternative splice variant of human IL-4, IL-4δ2, on IL-4 activities in human monocytes and B cells. Cell. Immunol. (1999) 191:161-167. (Pubitemid 29091851)
60. LARCHE M, LAMB JR, O'HEHIR RE et al.: Functional evidence for a monoclonal antibody that binds to the human IL-4 receptor. Immunology (1988) 65:617-622. (Pubitemid 19031218)
61. GAVETT SH, O'HEARN DJ, KARP CL et al.: Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am. J. Physiol. (1997) 272:L253-L261.
62. ZURAWSKI SM, CHOMARAT P, DJOSSOU O et al.: The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J. Biol. Chem. (1995) 270:13869-13878.
63. SATO K, TSUCHIYA M, SALDANHA J et al.: Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. (1993) 53:851-856. (Pubitemid 23077873)
64. TSUNENARI T, KOISHIHARA Y, NAKAMURA A et al.: New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood (1997) 90:2437-2444. (Pubitemid 27392728)
65. JABARA HH, VERCELLI D, SCHNEIDER LC et al.: Interleukin-4 receptor expression by human B cells: functional analysis with a human interleukin-4 toxin, DAB389IL-4. J. Allergy Clin. Immunol. (1995) 95:893-900.
66. KREITMAN RJ, PURI RK, PASTAN I: Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. (1995) 55:3357-3363.
67. DEBINSKI W, OBIRI NI, PASTAN I et al.: A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. (1995) 270:16775-16780.
68. PURI RK, LELAND P, OBIRI NI et al.: Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood (1996) 87:4333-4339. (Pubitemid 26155030)
69. DEBINSKI W, MINER R, LELAND P et al.: Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271:22428-22433.
70. YOSHIMURA A: The CIS family: negative regulators of JAK-STAT signaling. Cytokine Growth Factor Rev. (1998) 9:197-204. (Pubitemid 29019705)
71. STARR R, HILTON DJ: Negative regulation of the JAK/STAT pathway. Bioassays (1999) 21:47-52. (Pubitemid 29073018)
72. CHUNG CD, LIAO J, LIU B et al.: Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 278:1803-1805. (Pubitemid 27527648)
73. LIU B, LIAO J, RAO X et al.: Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. USA (1998) 95:10626-10631. (Pubitemid 28413118)